When was China's first test-tube baby born? March 10, 1988, a medical milestone

March 10, 1988: The Starting Point of Assisted Reproductive Technology in China

China's first test-tube baby was born on March 10, 1988 at Peking University Third Hospital. The reproductive medicine team led by Professor Zhang Lizhu successfully achieved this through in vitro fertilization-embryo transfer (IVF-ET) technology. The baby was a girl, weighing 3900 grams, with a normal Apgar score, and both mother and baby were safe. This event marked the official start of assisted reproductive technology in China, filling a domestic gap in this field and making China one of the few countries in the world to master test-tube baby technology.

The mother of the first test-tube baby had primary infertility due to bilateral tubal blockage and had previously tried various treatments without success. After strict patient screening, medical evaluation, and ethical review, Zhang Lizhu's team performed IVF-ET treatment, resulting in a successful pregnancy and full-term delivery.

Ten Years of Preparation Behind the Technological Breakthrough

The success of China's first test-tube baby was no accident. As early as 1978, after the world's first test-tube baby was born in the UK, Professor Zhang Lizhu's team began to pay attention to and plan related research. The entire preparation period spanned more than 10 years, including three stages: animal experiments, ethical论证, and technical breakthroughs.

• Animal Experiment Stage (1978–1985): The team repeatedly conducted in vitro fertilization and embryo transfer experiments on animal models such as mice and rabbits to verify the feasibility of the technical pathway and optimize culture medium formulations, fertilization conditions, and embryo manipulation procedures.
• Ethical and Regulatory Preparation (1985–1987): Within the medical ethical framework of the time, the team submitted multiple applications to the hospital's academic committee and health authorities, discussing the ethical boundaries of assisted reproductive technology, patient informed consent, and embryo disposal standards.
• Preclinical Technical Validation (1986–1987): After obtaining ethical approval, the team began recruiting volunteers for preclinical trials, including optimization of ovarian stimulation protocols, determination of egg retrieval timing, and improvement of in vitro fertilization rates.

By the end of 1987, the team had the technical conditions to perform clinical IVF-ET and had established a complete set of operational standards and quality control systems.

Key Decisions by Professor Zhang Lizhu's Team

Professor Zhang Lizhu has repeatedly emphasized in retrospect that the success of the first test-tube baby relied on several key decisions:

1. Patient Selection Criteria: Choosing a clear and irreversible infertility indication like tubal blockage, avoiding cases with complex causes and uncertain prognoses, to ensure the scientific validity of the technical validation.
2. Natural Cycle Strategy: Under conditions where recombinant follicle-stimulating hormone (FSH) was not available, the team adopted natural cycles or mild stimulation protocols to reduce the potential impact of drug intervention on oocyte quality.
3. Laboratory Quality Control: The construction standards of the embryo culture laboratory referenced international levels at the time, with 24-hour monitoring of temperature, humidity, and gas concentrations to ensure a stable embryo development environment.
4. Ethics First: All treatment plans were reviewed case by case by the hospital's ethics committee. Patients and their families signed detailed informed consent forms, clearly stating the technical success rate and possible risks.

These decisions established a basic paradigm for the standardized development of domestic assisted reproductive technology.

Technical Process of the First Test-Tube Baby

By today's standards, the technical process for the first test-tube baby was relatively basic, but it already covered the core steps of IVF-ET. The following is the actual operational process at that time:

The entire cycle from follicle monitoring to transfer took about 3–4 weeks. Biochemical pregnancy was confirmed by serum hCG detection on day 14 post-transfer, and fetal heartbeat was visible on ultrasound at week 6, confirming clinical pregnancy.

Practitioner's Perspective: The Industry Significance of Going from 0 to 1

As a practitioner in the assisted reproductive industry, reflecting on the technical path of the first test-tube baby, several observations are worth sharing.

First, the establishment of technical confidence. Before this first success, domestic research was sporadic and largely exploratory. The success in 1988 proved that Chinese reproductive medicine teams were capable of independently performing highly complex assisted reproductive technology, directly promoting the establishment of reproductive centers at institutions like Peking Union Medical College Hospital, the Reproductive Hospital Affiliated to Shandong University, and Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

Second, the prototype of a quality control system. The laboratory operational standards, embryo evaluation criteria, and clinical follow-up system established by Zhang Lizhu's team during the first test-tube baby procedure became the prototype for China's first batch of quality control documents for assisted reproductive technology. When the National Health Commission issued the "Administrative Measures for Human Assisted Reproductive Technology" in 2001, some technical standards referenced the team's experience.

Third, the starting point of patient education. The success of the first test-tube baby conveyed a key message to society: infertility can be effectively treated through scientific means. This directly influenced public awareness and acceptance of assisted reproductive technology in the following decades.

Frequently Asked Question: Current Status of the First Test-Tube Baby

In clinical consultations, patients often ask about the subsequent situation of China's first test-tube baby. The following is publicly available medical follow-up information:

• Healthy Growth: The first test-tube baby showed normal growth and development indicators after birth, with no significant differences in intelligence and physical development compared to naturally conceived children at various ages.
• Natural Fertility: As an adult, she married naturally and had children through natural conception, proving her reproductive function is completely normal.
• Long-term Health: As of the last public follow-up (2018), the individual was in good health with no chronic diseases or genetic abnormalities.

This result is consistent with large-scale cohort studies worldwide: individuals born through IVF-ET technology do not have a significantly increased long-term health risk compared to those conceived naturally.

Clarification of Common Misconceptions

There are some widespread misunderstandings about China's first test-tube baby, which are explained below.

Doctor's Advice: Lessons from History for Today

More than 35 years have passed since the first test-tube baby, and China's assisted reproductive technology has entered the international advanced ranks. For patients currently considering or about to undergo assisted reproductive treatment, the following reference opinions can be offered based on this history:

• Technological maturity has greatly improved: Today, the clinical pregnancy rate for IVF-ET in people under 35 can reach 50%–60%, far higher than the 1988 level. Age is the most critical factor affecting success rates, and patients with clear indications are advised to seek evaluation as early as possible.
• High degree of process standardization: The National Health Commission implements strict access management for assisted reproductive technology. All正规 reproductive centers must follow uniform technical standards and ethical guidelines. Choosing a qualified center with a historical track record is more reliable.
• Individualized plans are the trend: Unlike the natural cycle used for the first test-tube baby, current plans are highly individualized, including the choice of ovulation induction protocol, embryo culture method (conventional IVF or ICSI), and transfer strategy (fresh or frozen-thawed embryos). Doctors will formulate plans based on the patient's specific situation.
• Sufficient long-term follow-up data: Large-scale domestic and international studies have confirmed that the impact of IVF-ET technology on the long-term health of mothers and children is within an acceptable range. For patients who need treatment, the safety of the technology has been fully verified.

This content is compiled based on public medical literature, historical materials, and consensus within the assisted reproductive industry, aiming to provide objective knowledge reference. Individual situations vary; please consult a licensed physician at a正规 reproductive center for specific medical needs.